Mohamed Kamel Hussein

Thoracic Surgery, Surgical Oncology, General Surgery.

[Brendon Stiles @BrendonStilesMD]

@StephenVLiu @JTOonline Interesting series with very similar results to our previous NCDB study. Only 28% of mortality was after documented acute toxicity, suggesting that patient selection may be an issue. I continue to be surprised that only 34% had biopsy confirmation.

https://t.co/A6Je9fTIVZ

[Mohamed Kamel Hussein @MKamelHusseinMD]

@huroqu90 @nchudgar @MarcV_MD @RogerZhuMD @RajikaJindani Best of luck my friend. Amazing person, clinician, researcher, and future thoracic surgeon. You will be up to great things.

[Brendon Stiles @BrendonStilesMD]

This is an exceptionally good thread for surgeons, radiation oncologists, and oncologists interested in neoadjuvant and perioperative therapy for patients with locally advanced esophageal cancer. #ASCO24

[Ozlem Bilen MD🫀FACC @ozlembilen2]

WHAT is goin on #cardionerds? 🤓
(sound on)
Echo of the week
#echofirst #cvimaging

[Mohamed Kamel Hussein @MKamelHusseinMD]

@Chad_Rusthoven @BrendonStilesMD @StokedStokes @DrewMoghanaki @huroqu90 @nchudgar A matched analysis of patients who were offered but refused surgery and underwent SBRT (operable by definition) compared to minimally invasive SLR showed superior OS with surgery, I guess that addresses potential confounding factors. Any thoughts on that?

[Dominique Vervoort @DVervoort94]

Dr. @LarsSvenssonMD: "How do you stimulate innovation?"

Dr. @drpatrick: "Most of us, of our students, have it in them if they are given the chance. Give people the opportunity."

👏👏👏

#AATS2024

[Mohamed Kamel Hussein @MKamelHusseinMD]

@BrendonStilesMD @LindaMThoracic @huroqu90 @nchudgar @EinsteinMed @AATSHQ @AATSJournals Thanks Dr. Martin and Dr. Stiles for your feedback and support, I deleted my post and reposted after editing to avoid any misunderstanding.

[Mohamed Kamel Hussein @MKamelHusseinMD]

@huroqu90 @nchudgar @BrendonStilesMD @EinsteinMed @AATSHQ @AATSJournals The propensity matched comparison only included SBRT patients who were offered surgery but refused, therefore they by definition could have tolerated surgery and have adequate PFTs and performance status.

[Mohamed Kamel Hussein @MKamelHusseinMD]

@LindaMThoracic @huroqu90 @nchudgar @BrendonStilesMD @EinsteinMed @AATSHQ @AATSJournals @LindaMThoracic @BrendonStilesMD that was my full reply that had to be divided for words limit.

[Mohamed Kamel Hussein @MKamelHusseinMD]

@LindaMThoracic @huroqu90 @nchudgar @BrendonStilesMD @EinsteinMed @AATSHQ @AATSJournals My argument was for surgery, and our study shows superiority of sublobar resection compared to SBRT. We had a heated discussion with radiation oncology colleagues. I wish you get a chance to follow the whole thread. We had a link to the study abstract in the original post.

[Weill Cornell Medicine Cardiothoracic Surgery @WCM_CTSurgery]

🙏❤️🧡💛

[Mohamed Kamel Hussein @MKamelHusseinMD]

With Dr. Brendon Stiles, who I am profoundly proud and blessed to be one of his many mentees. @BrendonStilesMD #AATS2024

[Mohamed Kamel Hussein @MKamelHusseinMD]

@BrendonStilesMD @JCO_ASCO @_ShankarSiva @DrewMoghanaki @SBRT_CR @AATSHQ @samsonpp @ElliotServaisMD @DoctorJSpicer @biniamkidaneMD @IsaOpitz

[Mohamed Kamel Hussein @MKamelHusseinMD]

@huroqu90 @nchudgar @BrendonStilesMD @EinsteinMed @AATSHQ @AATSJournals We appreciate all your comments and happy to share the data and get your collaboration. Our aim is to provide the optimal care to the patients as I am sure is yours.

[Mohamed Kamel Hussein @MKamelHusseinMD]

@huroqu90 @nchudgar @BrendonStilesMD @EinsteinMed @AATSHQ @AATSJournals As mentioned in the abstract, in the surgery group almost a quarter of patient were pathologically upstaged to stage 2 or more on final path. I don't think there is any data to support using SBRT for stage 2 disease.

[Mohamed Kamel Hussein @MKamelHusseinMD]

@huroqu90 @nchudgar @BrendonStilesMD @EinsteinMed @AATSHQ @AATSJournals We agree that SBRT is overall safe treatment modality, but so is minimally invasive limited resection. The downside of SBRT remains the inability to address locoregional nodal disease.

[Mohamed Kamel Hussein @MKamelHusseinMD]

@huroqu90 @nchudgar @BrendonStilesMD @EinsteinMed @AATSHQ @AATSJournals Compating SBRT and lobectomy is invalid for many reasons including that sublobar rx is now the standard of care for NSCLC 2 cm or less. The 90d post SBRT mortality was calculated in the same manner like the JCO paper (time of first radiation to time of death/last follow up).

[Jorge Humberto Rodríguez Quintero MD, MPH @huroqu90]

“ADPRH is a novel tumor suppressor that may help identify tumors that benefit from anti-ART blockade” Absolutely thrilled and honored for the opportunity to present our work at @AATSHQ #AATS2024 @BrendonStilesMD @nchudgar @MontefioreNYC @EinsteinMed

[Brendon Stiles @BrendonStilesMD]

Pleased to share full text link to AATS 2023 Expert Consensus Document: Staging & multidisciplinary management of patients w/ early-stage non-small cell lung cancer.

Incredible team effort led by @biniamkidaneMD @DoctorJSpicer & Matt Bott. @AATSHQ #lcsm
https://t.co/voYwIk12uU

[Mohamed Kamel Hussein @MKamelHusseinMD]

@BrendonStilesMD @thoracic Congratulations Humberto